181 related articles for article (PubMed ID: 36661028)
1. Application of next-generation sequencing in diffuse large B-cell lymphoma.
Wang Y; Jia S; Cao X; Ge S; Yu K; Chen Y
Pharmacogenomics; 2023 Jan; 24(1):59-68. PubMed ID: 36661028
[TBL] [Abstract][Full Text] [Related]
2. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
3. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Dubois S; Viailly PJ; Mareschal S; Bohers E; Bertrand P; Ruminy P; Maingonnat C; Jais JP; Peyrouze P; Figeac M; Molina TJ; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Salles G; Tilly H; Leroy K; Jardin F
Clin Cancer Res; 2016 Jun; 22(12):2919-28. PubMed ID: 26819451
[TBL] [Abstract][Full Text] [Related]
5. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
Crombie JL; Armand P
Hematol Oncol Clin North Am; 2019 Aug; 33(4):575-585. PubMed ID: 31229155
[TBL] [Abstract][Full Text] [Related]
6. [Pathobiology and its clinical relevance in diffuse large B-cell lymphoma].
Ennishi D
Rinsho Ketsueki; 2023; 64(9):1026-1031. PubMed ID: 37899179
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.
Li XY; Wu JC; Liu P; Li ZJ; Wang Y; Chen BY; Hu CL; Fei MY; Yu PC; Jiang YL; Xu CH; Chang BH; Chen XC; Zong LJ; Zhang JY; Fang Y; Sun XJ; Xue K; Wang L; Chen SB; Jiang SY; Gui AL; Yang L; Gu JJ; Yu BH; Zhang QL; Wang L
Leukemia; 2023 Jan; 37(1):164-177. PubMed ID: 36352191
[TBL] [Abstract][Full Text] [Related]
8. Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
Saburi M; Sakata M; Kodama Y; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
J Clin Exp Hematop; 2023 Sep; 63(3):201-204. PubMed ID: 37518271
[No Abstract] [Full Text] [Related]
9. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
10. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
[TBL] [Abstract][Full Text] [Related]
11. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
Sert F; Kamer S; Saydam G; Anacak Y
J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
13. Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma.
Zou L; Song G; Gu S; Kong L; Sun S; Yang L; Cho WC
Curr Cancer Drug Targets; 2019; 19(9):681-687. PubMed ID: 31142246
[TBL] [Abstract][Full Text] [Related]
14. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH
Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832
[TBL] [Abstract][Full Text] [Related]
15. Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
Mondello P; Mian M
Hematol Oncol; 2019 Oct; 37(4):333-344. PubMed ID: 30938848
[TBL] [Abstract][Full Text] [Related]
16. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS; Czuczman MS
Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
[TBL] [Abstract][Full Text] [Related]
17. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
[TBL] [Abstract][Full Text] [Related]
18. Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
Jeon Y
Korean J Intern Med; 2023 Nov; 38(6):785-786. PubMed ID: 37939662
[No Abstract] [Full Text] [Related]
19. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
[TBL] [Abstract][Full Text] [Related]
20. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
